Plus Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new institutional investors and Company insiders to issue up to an aggregate of 3,238,627 shares of its common stock at an issue price of $2.022 per share for the gross proceeds of $6,548,503.794; Series A warrants to purchase up to an aggregate of 3,238,627 shares of common stock at an exercise price of $1.772 per share for an aggregate gross proceeds of up to $5,738,847.044 and Series B warrants to purchase up to 3,238,627 shares of common stock at an exercise price of $1.772 per share for an aggregate of up to approximately $5,738,847.044 for the aggregate gross proceeds of $17,948,503.794 on May 5, 2024. The Series B warrants will be exercisable until the one-year anniversary of the effectiveness of a registration statement covering the resale of shares of common stock underlying the Series B warrants. The private placement is expected to close on or about May 8, 2024, subject to satisfaction of customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 USD | -3.63% | -12.68% | +6.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.28% | 10.61M | |
+35.14% | 51.51B | |
-7.43% | 39.03B | |
+34.15% | 38.91B | |
-10.62% | 26.68B | |
+11.63% | 26.13B | |
-17.77% | 19.91B | |
+40.52% | 13.71B | |
+30.70% | 12.38B | |
-3.41% | 11.74B |
- Stock Market
- Equities
- PSTV Stock
- News Plus Therapeutics, Inc.
- Plus Therapeutics, Inc. announced that it expects to receive $6.548504 million in funding from Aigh Capital Management, LLC